Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT04663347
Title	Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL) (EPCORE™ NHL-2)
Acronym	EPCORE™ NHL-2
Recruitment	Recruiting
Gender	both
Phase	Phase Ib/II
Variant Requirements	No
Sponsors	Genmab
Indications	non-Hodgkin lymphoma diffuse large B-cell lymphoma follicular lymphoma
Therapies	Epcoritamab-bysp Cisplatin + Cytarabine + Dexamethasone + Epcoritamab-bysp + Rituximab Epcoritamab-bysp + Gemcitabine + Oxaliplatin Epcoritamab-bysp + Lenalidomide + Rituximab Bendamustine + Epcoritamab-bysp + Rituximab Cyclophosphamide + Doxorubicin + Epcoritamab-bysp + Prednisone + Rituximab + Vincristine Sulfate Epcoritamab-bysp + Lenalidomide
Age Groups:	adult \| senior
Covered Countries	USA \| SWE \| NOR \| NLD \| ITA \| GBR \| FRA \| FIN \| ESP \| DNK \| CZE \| BEL \| AUS